Adib, Elio
El Zarif, Talal
Nassar, Amin H. http://orcid.org/0000-0002-8084-9105
Akl, Elie W.
Abou Alaiwi, Sarah http://orcid.org/0000-0002-7073-3432
Mouhieddine, Tarek H.
Esplin, Edward D. http://orcid.org/0000-0001-9205-3756
Hatchell, Kathryn http://orcid.org/0000-0003-0849-7018
Nielsen, Sarah M.
Rana, Huma Q.
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Kwiatkowski, David J. http://orcid.org/0000-0002-5668-5219
Sonpavde, Guru http://orcid.org/0000-0002-1010-9611
Article History
Received: 8 September 2021
Revised: 19 November 2021
Accepted: 8 December 2021
First Online: 23 December 2021
Competing interests
: DJK reports serving as a consultant for Novartis and AADi. TKC reported receiving institutional and personal funds from Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi/Aventis, Takeda; reported receiving honoraria from the Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Lilly, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc. (Healthcare Communications Company with several brands, such as OnClive, PeerView, and PER), L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology; having a consulting or advisory role at Analysis Group, AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN. No speaker’s bureau. No leadership or employment in for-profit companies. Other present or past leadership roles: Director of GU Oncology Division at Dana-Farber and past President of Medical Staff at Dana-Farber), member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee). Patents, royalties, or other intellectual properties: International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response”, filed January 3, 2018, claiming priority to U.S. Provisional Patent Application No. 62/445,094, filed January 11, 2017; International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy,” filed October 31, 2018, claiming priority to U.S. Provisional Patent Application No. 62/581,175, filed November 3, 2017. Travel, accommodations, expenses, in relation to consulting, advisory roles, or honoraria. Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies (ClinicalThinking, Envision Pharma Group, Fishawack Group of Companies, Health Interactions, and Parexel, others). The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. CV provided upon request for the scope of clinical practice and research. EDE, KH, and SN are employees of Invitae Corporation, a testing laboratory that furnished the diagnostic test results used in this study. EDE and KH reported being a shareholder of Invitae. GS: Advisory board: Pfizer, BMS, Genentech, EMD Serono, Novartis, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Amgen, Eisai, Bicycle Therapeutics; research support to institution: Boehringer-Ingelheim, Bayer, Pfizer, Merck, Sanofi, Astrazeneca; Travel costs: BMS, Astrazeneca; speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Clinical Care Options; writing fees: Uptodate; steering committee of trials: BMS, Bavarian Nordic, Seattle Genetics, QED (all unpaid), and Astrazeneca and Debiopharm (both paid).
: Western Institutional Review Board protocol number 1167406 waived the requirement to obtain written patient informed consent. The study was performed in accordance with the Declaration of Helsinki.